Erratum: A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats (Cardiovascular Research (2009) 81:3 (601-609) DOI: 10.1093/cvr/cvn315);A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 601-609

  Hermida, Nerea ^a   López, Begoña ^a   González, Arantxa ^a   Dotor, Javier ^a   Lasarte, Juan José ^a   Sarobe, Pablo ^a   Borrás Cuesta, Francisco ^a   Díez, Javier ^a,b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Collagen; Hypertension; Myocardial fibrosis; Transforming growth factor 1

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; ISOPROTEIN; MESSENGER RNA; PEPTIDE P144; PROCOLLAGEN; PROTEIN LYSINE 6 OXIDASE; RECEPTOR SUBTYPE; SMAD2 PROTEIN; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COLLAGEN METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; HEART MUSCLE FIBROSIS; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION; WISTAR KYOTO RAT;

EID: 59449111178     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvaa232     Document Type: Erratum

References (39)

1. Díez J, González A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005;2:209-216.
2. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000;71:418- 435.
3. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-490.
4. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U et al. Alterations of beta-adrenergic signalling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002;283:H1253-H1262.
5. 1 heterozygous mice. J Mol Cell Cardiol 2000;32:187-195.
6. Jesmin S, Hattori Y, Togashi H, Ueno K, Yoshioka M, Sakuma I. Age-related changes in cardiac expression of VEGF and its angiogenic receptor KDR in stroke-prone spontaneously hypertensive rats. Mol Cell Biochem 2005;272:63-73.
7. Shiota N, Rysä J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003;21:1935-1944.
8. Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000;36:517- 522.
9. Scaglione R, Argano C, Di Chiara T, Parrinello G, Colomba D, Avellone G et al. Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens 2007;21:307-315.
10. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 2001;276:14588-14596.
11. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortázar I, Bustos M, Peñuelas I et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 2003;22:12-20.
12. Santiago B, Gutierrez-Cañas I, Dotor J, Palao G, Lasarte JJ, Ruiz J et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450-455.
13. US National Institutes of Health. Guide for the care and use of laboratory animals. Washington, DC: 1996, NIH Publication No. 85-23.
14. Lovernberg W. Techniques for the measurement of blood pressure. Hypertension 1987;9:15-16.
15. Lijnen P, Petrov V, Turner M, Fagard R. Collagen production in cardiac fibroblasts during inhibition of aminopeptidase B. JRAAS 2005;6:69-77.
16. Goikoetxea MJ, Beaumont FJ, González A, López B, Querejeta R, Larman M et al. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovasc Res 2006;69:899-907.
17. Dolber PC, Spach MS. Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol 1987;62:23-26.
18. López B, González A, Querejeta R, Larman M, Díez J. Alterations of the pattern of collagen deposition may contribuye to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
19. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-743.
20. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-1152.
21. Golvano J, Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Polarity of immunogens: implications for vaccine design. Eur J Immunol 1990;20:2363-2366.
22. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu M, Montiel C et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999;17:107-114.
23. Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res 1994;75:23-32.
24. Massagué J, Like B. Cellular receptors for type β transforming growth factor. Ligand binding and affinity labelling in human and rodent cell lines. J Biol Chem 1985;260:2636-2645.
25. López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993;73:1435- 1444.
26. Bodo M, Baroni T, Carinci F, Becchetti E, Conte C, Bellucci C et al. Interleukin secretion, proteoglycan and procollagen α1 (I) gene expression in Crouzon fibroblasts treated with basic fibroblasts growth factor. Cytokine 2000;12:1280-1283.
27. Barnett JV, Moustakas A, Lin W, Wang XF, Lin HY, Galper JB et al. Cloning and development expression of the chick type II and type III TGF beta receptors. Dev Dyn 1994;199:12-27.
28. Qu R, Silver MM, Letarte M. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 1998;292:333-343.
29. Stenvers KL, Tursky ML, Harder KW, Kontouri N, Amatayakul-Chantler S, Grail D et al. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol 2003;23:4371-4385.
30. Brower GL, Gardner JD, Forman MF, Murray DB, Veloshenyuk T, Levick SP et al. The relationship between myocardial extracellular matrix remodelling and ventricular function. Eur J Cardiothorac Surg 2006;30:604-610.
31. González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr Opin Nephrol Hypertens 2005;14:428-434.
32. Su D-F. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006;21:486-491.
33. Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH et al. Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2007;293:H2093-H2100.
34. 1 in the vascular system. Cardiovasc Pathol 2005;14:28.
35. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF beta family signalling. Nature 2003;425:577-584.
36. Leask A. TGF-β, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007;74:207-212.
37. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-1904.
38. Chua CC, Chua BH, Zhao ZY, Krebs C, Diglio C, Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991;26:271-281.
39. 1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.